Epothilones in breast cancer: Review of clinical experience Journal Article
| Author: | Fornier, M. N. |
| Article Title: | Epothilones in breast cancer: Review of clinical experience |
| Abstract: | Background: Drugs that target microtubules, including paclitaxel (Taxol) and docetaxel (Taxotere), are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapies is limited by difficulties with formulation, administration, and resistance induced by P-glycoprotein. The epothilones are a novel class of antimicrotubule agents that have demonstrated antitumor activity in the setting of resistance. Design: This review summarizes clinical studies of epothilones in patients with metastatic breast cancer. Data were identified by searches of PubMed and the Proceedings of the American Society of Clinical Oncology annual meetings from 2000 to 2006. Results: The epothilones have demonstrated promising antitumor activity and manageable toxicity in phase II studies of heavily pretreated patients with metastatic breast cancer, including patients with resistance to taxanes and other cytotoxic agents. Neuropathy associated with ixabepilone appears to be schedule dependent and comparable to that observed with paclitaxel. Ixabepilone appears to be active in combination with capecitabine. Conclusions: Ongoing and planned trials promise to elucidate the benefits of ixabepilone in combination with other agents including capecitabine, bevacizumab, and trastuzumab in patients with metastatic breast cancer as well as those receiving neo-adjuvant therapy. © 2007 European Society for Medical Oncology. |
| Keywords: | treatment outcome; cancer surgery; clinical trial; fatigue; neutropenia; paresthesia; review; bevacizumab; cytotoxic agent; doxorubicin; diarrhea; drug dose reduction; drug efficacy; drug safety; drug withdrawal; monotherapy; recommended drug dose; antineoplastic agents; conference paper; capecitabine; paclitaxel; adjuvant therapy; cancer adjuvant therapy; neoadjuvant therapy; neurotoxicity; antineoplastic agent; carboplatin; metastasis; multiple cycle treatment; sensory neuropathy; breast cancer; blood toxicity; gastrointestinal symptom; leukopenia; neuropathy; stomatitis; myalgia; peripheral neuropathy; combination chemotherapy; clinical protocol; antineoplastic activity; breast neoplasms; cancer resistance; docetaxel; abdominal pain; arthralgia; backache; dizziness; drug dose escalation; drug fever; febrile neutropenia; loading drug dose; drug combination; drug therapy, combination; breast tumor; experience; nausea and vomiting; medline; weakness; taxane derivative; anthracycline derivative; trastuzumab; hand foot syndrome; metastatic breast cancer; neuropathic pain; ixabepilone; epothilones; epothilone d; epothilone derivative; tubulin modulator; tubulin modulators; epothilone; drug formulation; hypesthesia; phase ii clinical trial; kos-862; taxane-resistant |
| Journal Title: | Annals of Oncology |
| Volume: | 18 |
| Issue: | Suppl. 5 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2007-07-01 |
| Start Page: | v16 |
| End Page: | v21 |
| Language: | English |
| DOI: | 10.1093/annonc/mdm174 |
| PUBMED: | 17656557 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 8" - "Export Date: 17 November 2011" - "CODEN: ANONE" - "Source: Scopus" |
